Suppr超能文献

18-24 个月内无 HIV 生存作为评估在终身抗逆转录病毒治疗背景下母婴传播预防有效性的指标:基于社区的调查结果。

18-24-month HIV-free survival as measurement of the effectiveness of prevention of mother-to-child transmission in the context of lifelong antiretroviral therapy: Results of a community-based survey.

机构信息

Centre for International Health, University of Bergen, Bergen, Norway.

Elizabeth Glaser Pediatric AIDS Foundation, Washington D.C., United State of America.

出版信息

PLoS One. 2020 Oct 1;15(10):e0237409. doi: 10.1371/journal.pone.0237409. eCollection 2020.

Abstract

INTRODUCTION

Population-based HIV-free survival at 18-24 months of age among HIV-exposed infants in high prevalence settings in the era of treatment for all is largely unknown. We conducted a community-based survey to determine outcomes of HIV-exposed infants at 18-24 months in Lesotho.

METHODS

Between November 2015 and December 2016, we conducted a survey among households with a child born 18-24 months prior to data collection. Catchment areas from 25 health facilities in Butha-Buthe, Maseru, Mohale's Hoek and Thaba-Tseka districts were randomly selected using probability proportional to size sampling. Consecutive households were visited and eligible consenting caregivers and children were enrolled. Rapid HIV antibody testing was performed on mothers of unknown HIV status (never tested or tested HIV-negative >3 months prior) and their children, and to children born to known HIV-positive mothers. Information on demographics, health-seeking behavior, HIV, and mortality were captured for mothers and children, including those who died. The difference in survival between subgroups was determined using the log-rank test.

RESULTS

Of the 1,852 mothers/caregivers enrolled, 570 mothers were HIV-positive. The mother-to-child HIV transmission rate was 5.7% [95% CI: 4.0-8.0]. The mortality rate was 2.6% [95% CI: 1.6-4.2] among HIV-exposed children compared to 1.4% (95% CI: 0.9-2.3) among HIV-unexposed children. HIV-free survival was 91.8% [95% CI: 89.2-93.8] among HIV-exposed infants. Disclosure of mother's HIV status (aOR = 4.9, 95% CI: 1.3-18.2) and initiation of cotrimoxazole prophylaxis in the child (aOR = 3.9, 95% CI: 1.2-12.6) were independently associated with increased HIV-free survival while child growth problems (aOR = 0.2, 95% CI: 0.09-0.5) were independently associated with reduced HIV-free survival.

CONCLUSION

Even in the context of lifelong antiretroviral therapy among pregnant and breastfeeding women, HIV has a significant effect on survival among HIV-exposed children compared to unexposed children. Lesotho has not reached elimination of HIV transmission from mother to child.

摘要

简介

在所有治疗时代,高流行地区中接受艾滋病毒暴露的婴儿在 18-24 个月时的基于人群的艾滋病毒存活情况在很大程度上尚不清楚。我们在莱索托进行了一项社区调查,以确定在 18-24 个月时接受艾滋病毒暴露的婴儿的结局。

方法

2015 年 11 月至 2016 年 12 月期间,我们对在数据收集前 18-24 个月出生的儿童的家庭进行了一项调查。使用按大小成比例抽样法随机选择来自布塔-布泰、马塞卢、莫哈莱霍克和塔巴-采卡区 25 个卫生设施的集水区。连续访问家庭,并招募符合条件的同意的照顾者和儿童。对母亲的艾滋病毒状况未知的母亲(从未接受过检测或在 3 个月前检测艾滋病毒阴性)及其子女进行快速艾滋病毒抗体检测,对已知艾滋病毒阳性母亲所生的子女也进行检测。为母亲和儿童(包括死亡儿童)获取人口统计学、寻求医疗服务行为、艾滋病毒和死亡率信息。使用对数秩检验确定亚组之间的生存差异。

结果

在纳入的 1852 名母亲/照顾者中,有 570 名母亲为艾滋病毒阳性。母婴传播率为 5.7%[95%CI:4.0-8.0]。与未暴露于艾滋病毒的儿童相比,暴露于艾滋病毒的儿童的死亡率为 2.6%[95%CI:1.6-4.2],而未暴露于艾滋病毒的儿童的死亡率为 1.4%[95%CI:0.9-2.3]。暴露于艾滋病毒的婴儿的艾滋病毒无存活率为 91.8%[95%CI:89.2-93.8]。母亲艾滋病毒状况的披露(优势比[aOR]=4.9,95%置信区间[CI]:1.3-18.2)和儿童开始使用复方新诺明预防(aOR=3.9,95%CI:1.2-12.6)与增加的艾滋病毒无存活率相关,而儿童生长问题(aOR=0.2,95%CI:0.09-0.5)与降低的艾滋病毒无存活率相关。

结论

即使在艾滋病毒感染孕妇和哺乳期妇女终身接受抗逆转录病毒治疗的情况下,艾滋病毒对暴露于艾滋病毒的儿童的生存也有显著影响,而对未暴露于艾滋病毒的儿童没有影响。莱索托尚未达到消除母婴传播艾滋病毒的目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfa/7529246/6d914fb623eb/pone.0237409.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验